M&A Deal Summary

Integra LifeSciences Holdings Acquires ACell

On December 16, 2020, Integra LifeSciences Holdings acquired medical products company ACell for 400M USD

Acquisition Highlights
  • This is Integra LifeSciences Holdings’ 36th transaction in the Medical Products sector.
  • This is Integra LifeSciences Holdings’ 2nd largest (disclosed) transaction.
  • This is Integra LifeSciences Holdings’ 36th transaction in the United States.
  • This is Integra LifeSciences Holdings’ 1st transaction in Maryland.

M&A Deal Summary

Date 2020-12-16
Target ACell
Sector Medical Products
Buyer(s) Integra LifeSciences Holdings
Deal Type Add-on Acquisition
Deal Value 400M USD
Advisor(s) Guggenheim Securities (Financial)
Cooley LLP (Legal)

Target

ACell

Columbia, Maryland, United States
website
ACell, Inc. is a medicine company focused on the development, manufacturing, and commercialization of medical devices for wound management and surgical soft tissue repair. ACell’s core product portfolio is based on our platform MatriStem UBM™ technology. Acell was founded in 2002 and is based in Columbia, Maryland.

Search 192,611 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Integra LifeSciences Holdings

Princeton, New Jersey, United States

website


Category Company
Founded 1989
Sector Medical Products
Employees3,800
Revenue 1.5B USD (2021)
DESCRIPTION

Integra LifeSciences Holdings is a major medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, and reconstructive and general surgery. Integra LifeSciences Holdings was founded in 1989 and is based in Princeton, New Jersey.


DEAL STATS #
Overall 43 of 45
Sector (Medical Products) 36 of 38
Type (Add-on Acquisition) 32 of 33
State (Maryland) 1 of 1
Country (United States) 36 of 38
Year (2020) 1 of 1
Size (of disclosed) 2 of 27
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-09-29 Integra LifeSciences Holdings - Extremity Orthopaedics Business

Princeton, New Jersey, United States

Integra LifeSciences Holdings Corp. - Extremity Orthopaedics Business includes shoulder replacement and upper and lower extremities portfolio, and an exciting new product pipeline. The focused extremities commercial channel includes a specialized sales force and distributors, predominantly in the US as well as Canada and Europe.

Sell $240M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-12-01 SIA

Chicago, Illinois, United States

SIA is a commercial-stage medical device company, committed to raising the standard of care in plastic, reconstructive, and general surgery and lowering systemic costs through “for surgeon, by surgeon” medical device innovation. The company’s flagship product family, DuraSorb Monofilament Mesh is on the market and indicated for use in the reinforcement of soft tissues where weakness exists. DuraSorb was specifically designed for plastic, reconstructive, and general surgery and is US FDA 510(k) cleared and CE marked. SIA was formed in 2016 and is based in Chicago, Illinois.

Buy -